The patent, which is the second notice of allowance from the USPTO in recent months, is expected to expire no earlier than October 2030.
iX Biopharma has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application on Tuesday (August 4).
The patent will provide key intellectual property protection for the Company's WaferiX delivery technology platform, and will provide a further barrier to generic entry in addition to iX Biopharma’s notice of allowance for its previous patent application which was issued earlier in 2020.
